DARIOHEALTH CORP. (NASDAQ:DRIO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

On December 19, 2019, DarioHealth Corp. (the “Company”) entered into subscription agreements (each, a “Series A-3 Subscription Agreement” and collectively the “Series A-3 Subscription Agreements”) with accredited investors relating to an offering (the “Offering”) and the sale of an aggregate of 1,346 shares of newly designated Series A-3 Preferred Stock, at a purchase price of $1,000 per share, for aggregate gross proceeds to the Company of $1,346,000.

The total aggregate gross proceeds of the Offering described above, together with gross proceeds from the closing of the offering of Series A Preferred Stock and Series A-1 Preferred Stock (as reported in the Company’s Current Reports on Forms 8-K and 8-K/A filings made with the Securities and Exchange Commission on December 3, 2019), and the offering of the Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series A-4 Preferred Stock (as reported in the Company’s Current Report on Form 8-K filing made with the Securities and Exchange Commission on December 6, 2019), was $21.375 million.

The Company previously filed a Certificate of Designation of Preferences, Rights and Limitations of Series A-3 Preferred Stock on December 4, 2019 (the “A-3 Effective Date”), designating 12,500 shares of Series A-3 Preferred Stock, in connection with the Offering.

Each share of Series A-3 Preferred Stock is convertible at the option of the holder, subject to certain beneficial ownership limitations as set forth in the Series A-3 Certificate of Designation into such number of shares of Company’s common Stock (the “Common Stock”) equal to the number of Series A-3 Preferred Shares to be converted, multiplied by the stated value of $1,000 (the “Stated Value”), divided by the conversion price in effect at the time of the conversion (the initial conversion price for the Series A-3 Preferred Stock was $4.98, subject to adjustment in the event of stock splits, stock dividends, and similar transactions). In addition, the Series A-3 Preferred Stock will automatically convert into shares of Common Stock, subject to certain beneficial ownership limitations, on the earliest to occur of (i) upon the approval of the holders at least 50.1% of the outstanding shares of Series A-3 Preferred with respect to the Series A-3 Preferred Stock; or (ii) the 36-month anniversary of each of the Series A-3 Effective Date. The holders of Series A-3 Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock issuable upon conversion of the Series A-3 Preferred Stock then held by such holder on the 12-month anniversary of the Series A-3 Effective Date, (ii) a number of shares of Common Stock equal to fifteen percent (15%) of the number of shares of Common Stock issuable upon conversion of the Series A-3 Preferred then held by such holder on the 24-month anniversary of the Series A-3 Effective Date, and (iii) a number of shares of Common Stock equal to twenty percent (20%) of the shares of Common Stock issuable upon conversion of the Series A-3 Preferred Stock then held by such holder on the 36-month anniversary of the Series A-3 Effective Date.

The Series A-3 Preferred Stock will vote together with the Common Stock as a single class on an as-converted basis on any matter presented to the shareholders of the Company. Upon any liquidation, dissolution or winding-up of the Company, after the satisfaction in full of the debts of the Company and payment of the liquidation preference to the Senior Securities, holders of Series A-3 Preferred Stock shall be entitled to be paid, on a pari passu basis with the payment of any liquidation preference afforded to holders of any Parity Securities, the remaining assets of the Company available for distribution to its stockholders. For these purposes, (i) “Parity Securities” means the Common Stock, Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock and any other class or series of capital stock of the Company hereinafter created that expressly ranks pari passu with the Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series A-4 Preferred Stock; and (ii) “Senior Securities” shall mean any class or series of capital stock of the Company hereafter created which expressly ranks senior to the Parity Securities.

The Company and the investors in the Offering also executed a registration rights agreement (the “Registration Rights Agreement”), to which the Company agreed to file a registration statement covering the resale of the shares of Common Stock issuable upon conversion of the Series A-3 Preferred Stock within sixty days following the final closing of the Offering.

to the Placement Agency Agreement (the “Placement Agency Agreement”) executed by and between the Company and the registered broker dealer retained to act as the Company’s exclusive placement agent (the “Placement Agent”) for the Offering, the Company paid the Placement Agent an aggregate cash fee of $132,100, non-accountable expense allowance of $40,380 and is required to issue to the Placement Agent or its designees warrants to purchase 39,229 shares of Common Stock at an exercise price of $4.98 per share (the “Placement Agent Warrants”). The Placement Agent Warrants are exercisable for a period of five years from the date of each respective closing.

The Subscription Agreements contains representations and warranties that the parties made to the others in the context of all of the terms and conditions of that agreement and in the context of the specific relationship between the parties. The provisions of such agreements, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreement and are not intended as documents for investors and the public to obtain factual information about the current state of affairs of the parties to that agreement. Rather, investors and the public should look to other disclosures contained in the Company’s filings with the U.S. Securities and Exchange Commission.

The securities to be issued in the Offering are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act and may not be resold in the United States absent registration or an exemption from registration. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The forgoing description of the Series A-3 Certificate of Designation is qualified in its entirety by reference to the full text of such document, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K, respectively. The forgoing descriptions of the Placement Agency Agreement, the Registration Rights Agreement, the Placement Agent Warrants and the Subscription Agreements are qualified by reference to the full text of these documents, copies of each of which will be filed in the Company’s next periodic report due to be filed under the Exchange Act.

The response to this item is included in Item 1.01, Entry into a Material Definitive Agreement, and is incorporated herein in its entirety.

(d)

Exhibits

3.1	Certificate of Designation of Preferences, Rights and Limitations of Series A-3 Preferred Stock (Incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2019).

 

About DARIOHEALTH CORP. (NASDAQ:DRIO)

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter. The Dario product is a digital diabetes management solution utilizing its technology delivered through a software application available for iPhone or Android and cloud-based data services with a blood glucose monitoring system device. Dario allows users to record, analyze, transmit and store various data points, such as glucose level, insulin and carbohydrate intake. It markets the Dario Smart Diabetes Management Solution in the Netherlands and New Zealand.